The UK’ Medicines and Healthcare products Regulatory Agency (MHRA) has today approved Exblifep, the combined antibiotic cefepime/enmetazobactam 2g/0.5g powder for concentrate for solution for infusion) to treat adult patients with complicated infections of the urinary tract (bladder and kidneys) and certain types of pneumonia that occur during a hospital stay.
Developed by Indian drugmaker Orchid Pharma, and sub-licensed to Advanz Pharma for marketing the UK, the combined antibiotic can also be used to treat bacteremia (bacteria in the blood) due to, or possibly due to, any of the infections listed above.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze